CEOs of Largest Global Companies Positive and Pushing for Growth, Arthur D. Little Research Finds
21.2.2023 15:00:00 EET | Business Wire | Press release
Arthur D. Little (ADL) today launched its 2023 CEO Insights Study, highlighting that the leaders of the world’s biggest companies are confident despite the current turmoil. Sixty-three percent expect a stable or positive economic outlook over the next three to five years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230221005413/en/
Arthur D. Little CEO Insights 2023: Turning turmoil to advantage: How CEOs are navigating change to drive growth (Graphic: Business Wire)
Despite the downturn, CEOs are focused on growth – half say they will enter new geographies, and 30 percent expect to grow faster than the wider market. Even cautious CEOs expect to increase growth investments, with 40 percent spending more and 55 percent keeping expenditure constant. At the same time, leading CEOs are becoming truly ambidextrous, combining this innovation with laser focus on cost optimization.
CEO confidence in the future can be attributed to the lessons learned from the pandemic, which forced many businesses to transform their operations. Ninety-one percent of CEOs understand that developing fit-for-purpose capabilities that drive optimization and efficiency, as well as innovation and growth, are now mission critical. This is likely to lead to a different capability mix enabling companies to unleash their full potential moving forward.
However, there are differing pictures between regions. Thirty-eight percent of European CEOs in the top five economies of France, Germany, Italy, Spain, and the UK expect to see a positive economic outlook over the next three to five years, against just 25 percent of those in North America and 10 percent in Asia.
CEOs see technology innovation as the most critical factor to company growth, and are moving beyond digitalization to embrace technologies such as AI, robotics and automation. They are also looking forward – 60 percent want to explore new technologies, and 27 percent believe the metaverse and virtual reality will impact their business.
Hearteningly, 80 percent of CEOs believe focusing on environmental, social and governance (ESG) delivers competitive advantage, rather than simply being a compliance cost. In fact, 41 percent of CEOs rank it as a higher priority than all other initiatives.
Francesco Marsella, Managing Partner and Global Practice Leader, Strategy & Organization at Arthur D. Little, comments: “In a downturn, conventional business wisdom is to cut costs and focus on survival. Despite current challenges and many dark macroeconomic predictions for 2023, most CEOs we spoke to are optimistic for the future, working with passion, entrepreneurship, and creativity to manage performance today while building for the future. They see opportunity in adversity, looking beyond the current crisis to embrace a more positive future for their companies and wider society.”
The Arthur D. Little 2023 CEO Insights Study interviewed nearly 250 global CEOs leading companies with a turnover of more than USD 1 billion. Fifty-five percent of the sample employed over 10,000 people. Study respondents are split between key industries and geographies to give unrivaled insight into the minds of those running the world’s biggest organizations.
The full report, including recommendations from ADL, can be downloaded from https://tinyurl.com/ypc7yvx4.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005413/en/
Contact information
Further information from:
Cate Bonthuys / Sue Glanville
Catalyst Comms
+44 7715 817589
info@catalystcomms.co.uk
For further information, please visit www.adlittle.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
